Agios Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 68 to 73 Thursday — a welcome improvement, but still below the 80 or better score you look for.
Can You Really Time The Stock Market?
IBD's proprietary rating measures price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 as they begin their largest climbs. See if Agios Pharmaceuticals can continue to rebound and clear that threshold.
Agios Pharmaceuticals broke out earlier, but has fallen back below the prior 41.74 entry from a consolidation. If a stock you're watching clears a buy point then falls 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new base and breakout. Also understand that the latest consolidation is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one.
The company posted 0% EPS growth in its most recent report. Sales gains came in at 45%. Look for the next report on or around Oct. 30.
The company holds the No. 249 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
